Update on new experimental Alzheimer’s drug

Published On: April 5, 2021
Shared by

According to early clinical trial results, recently published in The New England Journal of Medicine, a new experimental intravenous drug donanemab could slow cognitive decline.

Click HERE to read the full story.

Article Categories: News, Newsletter